ArticleScientific reports2021
The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- NCAPG2 is a diagnostic biomarker associated with immune infiltration in cholangiocarcinoma.Discover oncology · 2025Article
- Pan-cancer analysis shows that TNFSF4 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including liver cancer.BMC cancer · 2025Article
- Article
- Construction and validation of a ubiquitination-related prognostic risk score signature in breast cancer.Heliyon · 2024Article
- A multi-organ map of the human immune system across age, sex and ethnicity.bioRxiv : the preprint server for biology · 2024Article
- Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients.Frontiers in immunology · 2024Review
- High Expression ofGenes · 2023Article
- Genome-wide association study of mammary gland tumors in Maltese dogs.Frontiers in veterinary science · 2023Article
- Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma.Journal of oncology · 2023Article
- Stem signatures associating SOX2 antibody helps to define diagnosis and prognosis prediction with esophageal cancer.Annals of medicine · 2022Article
- Integrative analysis identifies three molecular subsets in ovarian cancer.Clinical and translational medicine · 2022Article
- Bioinformatics analysis of lncRNAs in the occurrence and development of osteosarcoma.Translational pediatrics · 2022Article
- Identification of an Immune-Related Gene Signature Associated with Prognosis and Tumor Microenvironment in Esophageal Cancer.BioMed research international · 2022Article
- A tumor microenvironment-related risk model for predicting the prognosis and tumor immunity of breast cancer patients.Frontiers in immunology · 2022Article
- Identification and verification of immune-related gene prognostic signature based on ssGSEA for breast cancer.Central-European journal of immunology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint blockade, an immunotherapy, has been applied in multiple systemic malignancies and has improved overall survival to a relatively great extent; whether it can be applied in breast cancer remains unknown. We endeavored to explore possible factors that may influence immunotherapy outcomes in breast cancer using several public databases. The possible treatment target TNF superfamily member 4 (TNFSF4) was selected from many candidates based on its abnormal expression profile, survival-associated status, and ability to predict immune system reactions. For the first time, we identified the oncogenic features of TNFSF4 in breast carcinoma. TNFSF4 was revealed to be closely related to treatment that induced antitumor immunity and to interact with multiple immune effector molecules and T cell signatures, which was independent of endocrine status and has not been reported previously. Moreover, the potential immunotherapeutic approach of TNFSF4 blockade showed underlying effects on stem cell expansion, which more strongly and specifically demonstrated the potential effects of applying TNFSF4 blockade-based immunotherapies in breast carcinomas. We identified potential targets that may contribute to breast cancer therapies through clinical analysis and real-world review and provided one potential but crucial tool for treating breast carcinoma that showed effects across subtypes and long-term effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.